As an early funder of Entrada, CureDuchenne is pleased to share that Entrada received authorization in the United Kingdom (UK) to start a Phase 1/2 trial for individuals with Duchenne amenable to exon 44 skipping.
Part A, which is planned to start in Q2 2025, will be a multiple-ascending dose study in 24 individuals with Duchenne, with doses administered every 6 weeks. Part B will further evaluate the optimal dose established.
Entrada has also submitted regulatory filings to initiate trials in the US and In Europe, and those regulatory discussions are ongoing.
Press release: https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-receives-authorization-united-kingdom-0
The post Entrada Therapeutics gets ok to start Exon 44 skipping trial in UK appeared first on CureDuchenne.